Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harbeck

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.
The International Journal of Biological Markers|April 14, 2000
A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implicationsF Noack, M Schmitt, J Bauer, et al.
Breast Cancer Research and Treatment|September 21, 2004
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrowC Schindlbeck, W Janni, N Shabani, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1995
[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma]N Harbeck, P Dettmar, Ch Thomssen, et al.
International Journal of Surgery (London, England)|October 10, 2015
Surgical management of ipsilateral breast tumor recurrenceT Kolben, T M Schwarz, C Goess, et al.
Journal of the National Cancer Institute|June 21, 2001
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1F Jänicke, A Prechtl, C Thomssen, et al.
Cancer|April 1, 1994
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagusT Nakamura, H Nekarda, A H Hoelscher, et al.
International Journal of Oncology|May 11, 2011
Model system for isolation of competent ovarian-carcinoma cells from fresh tumor-tissue by a magnetic separation technique (macs)N Harbeck, S Schwarze, E Schuren, et al.
British Journal of Cancer|January 1, 1997
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancerP Dettmar, N Harbeck, C Thomssen, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.
The International Journal of Biological Markers|April 14, 2000
A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implicationsF Noack, M Schmitt, J Bauer, et al.
Breast Cancer Research and Treatment|September 21, 2004
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrowC Schindlbeck, W Janni, N Shabani, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1995
[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma]N Harbeck, P Dettmar, Ch Thomssen, et al.
International Journal of Surgery (London, England)|October 10, 2015
Surgical management of ipsilateral breast tumor recurrenceT Kolben, T M Schwarz, C Goess, et al.
Journal of the National Cancer Institute|June 21, 2001
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1F Jänicke, A Prechtl, C Thomssen, et al.
Cancer|April 1, 1994
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagusT Nakamura, H Nekarda, A H Hoelscher, et al.
International Journal of Oncology|May 11, 2011
Model system for isolation of competent ovarian-carcinoma cells from fresh tumor-tissue by a magnetic separation technique (macs)N Harbeck, S Schwarze, E Schuren, et al.
British Journal of Cancer|January 1, 1997
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancerP Dettmar, N Harbeck, C Thomssen, et al.
Pageof 15